Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Girard Armand
 2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2019		 3. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [GLYC]
(Last)
(First)
(Middle)
C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Strategy & Corporate Dev
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ROCKVILLE, MD 20850		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (1) 04/20/2024 Common Stock 65,000 $ 14.14 D  
Employee Stock Option (right to buy)   (2) 01/07/2025 Common Stock 5,516 $ 7.15 D  
Employee Stock Option (right to buy)   (3) 01/06/2026 Common Stock 9,916 $ 5.22 D  
Employee Stock Option (right to buy)   (4) 01/03/2027 Common Stock 30,000 $ 6.33 D  
Employee Stock Option (right to buy)   (5) 01/09/2028 Common Stock 50,000 $ 20.03 D  
Employee Stock Option (right to buy)   (6) 01/16/2029 Common Stock 65,000 $ 10.59 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Girard Armand
C/O GLYCOMIMETICS, INC.
9708 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850		       SVP, Strategy & Corporate Dev  

Signatures

/s/ Brian F. Leaf, Attorney-in-fact 03/06/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 25% of the shares underlying this option vested on April 21, 2015 and the remaining 75% of the shares vested in 36 equal monthly installments through April 21, 2018.
(2) 25% of the shares underlying this option vested on January 8, 2016 and the remaining 75% of the shares vested in 36 equal monthly installments through January 8, 2019.
(3) 25% of the shares underlying this option vested on January 7, 2017 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 7, 2020.
(4) 25% of the shares underlying this option vested on January 4, 2018 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 4, 2021.
(5) 25% of the shares underlying this option vested on January 10, 2019 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 10, 2022.
(6) 25% of the shares underlying this option will vest on January 17, 2020 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 17, 2023.
 
Remarks:
Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.